Vicore Pharma Holding AB - C21 IPF AIR Study -- Interim Analysis Transcript
()-
Good day, everyone, and welcome to the Vicore AIR interim results webcast. I am Hans Jeppsson, CFO. I'm very proud to be hosting today's event. This recorded webcast is accessible via the Vicore website and will be available for replay later on today.
Today's speaker will be Carl-Johan Dalsgaard, CEO, who will go through the AIR study design and interim results. You'll see a PowerPoint presentation on screen while he's talking. We estimate that the presentation will take about 20 minutes, and this will be followed by a Q&A session. (Conference Instructions) At this point, I would like to hand over to Carl-Johan to kick things off.
()-
Thank you, Hans, and good afternoon, and good morning for those who just woke up. I'm very pleased and excited to share with you the remarkable results of the interim analysis of the Phase 2 study of C21, a first-in-class
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |